Skip to content

US · VCRE · BIOTECHNOLOGY

Vicore Pharma Holding AB (VCRE) intrinsic value and stock valuation

$10.35as of 2026-09-18 · Mkt cap 3B

Data updated · price as of 2026-09-18

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Vicore Pharma Holding AB DCF and intrinsic value

InvestorsCraft values VCRE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from VCRE’s statements →

Vicore Pharma Holding AB Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Stockholm, AB, SE vicorepharma.com

How the business is doing

Fiscal 2025–2021, USD

Revenue
$0.00
20252021
Net income
-$-294.97T
20252021
Free cash flow
-$-263.82T
20252021
Total equity
$1,095.5T
20252025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2025–2021, USD
FYFYFYFYFY
Revenue$3.82T$109.3T$0.00$0.00$0.00
Operating income-$-454.45T-$-190.36T-$-321.51T-$-290.73T-$-32.59T
Net income-$-477.47T-$-168.63T-$-310.94T-$-288.42T-$-294.97T
EPSd-$-19.9M-$-12.32M-$-32.2M-$-38.86M-$-4.23M
Operating cash flow-$-375.74T-$-164.95T-$-249.58T-$-299.92T-$-263.82T
Capital expenditure$0.00$0.00$0.00-$-3T$0.00
Free cash flow-$-375.74T-$-164.95T-$-249.58T-$-302.92T-$-263.82T
Total assets$1,218.6T————
Total debt$0.00————
Net debt-$-578.15T————
Total equity$1,095.5T————
Cash and short-term investments$1,166.7T————
Income statement
FYFYFYFYFY
Revenue$3.82T$109.3T$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$3.58T
Gross profit$3.82T$109.3T$0.00$0.00-$-3.58T
Research and development expenses$390.3T$249.3T$276.3T$250T$30T
Selling, general and administrative expenses$67.9T$50.4T$44.6T$37.5T$2.39T
Other expenses$0.00$0.00$617B$3.23T$154.5B
Operating expenses$458.3T$299.7T$321.5T$290.7T$32.6T
Cost and expenses$458.3T$299.7T$321.5T$290.7T$32.6T
Interest income$23.9T$21.1T$10.5T$913B$70.2B
Interest expense$60B$8B$2B$8B$0.00
Depreciation and amortization$0.00$2.24T$3.42T$3.61T$371.3B
Ebitda-$-477.41T-$-166.64T-$-307.9T-$-285.19T-$-32.07T
Operating income-$-454.45T-$-190.36T-$-321.51T-$-290.73T-$-32.59T
Total other income/expenses, net-$-23.03T$21.5T$10.2T$1.92T-$-211.92B
Income before tax-$-477.47T-$-168.89T-$-311.33T-$-288.81T-$-32.8T
Income tax expense$0.00-$-256B-$-384B-$-384B-$-252.7B
Net income-$-477.47T-$-168.63T-$-310.94T-$-288.42T-$-294.97T
Weighted average shares outstanding$24T$13.7T$9.66T$7.42T$69.7T
Weighted average diluted shares outstanding$24T$13.7T$9.66T$7.42T$69.7T
Balance sheet
FY
Cash and short-term investments$1,166.7T
Net receivables$0.00
Inventory$0.00
Total current assets$1,216.9T
Property, plant and equipment, net$0.00
Goodwill and intangible assets$0.00
Long-term investments$0.00
Total non-current assets$1.71T
Total assets$1,218.6T
Accounts payable$39.5T
Short-term debt$0.00
Deferred revenue$0.00
Total current liabilities$118.4T
Long-term debt$0.00
Deferred revenue, non-current$0.00
Total non-current liabilities$4.74T
Capital lease obligations$0.00
Total liabilities$123.2T
Common stock$140.8T
Retained earnings-$-1,920.92T
Accumulated other comprehensive income (loss)$0.00
Total equity$1,095.5T
Total investments$588.6T
Total debt$0.00
Net debt-$-578.15T
Cash flow statement
FYFYFYFYFY
Net income-$-452.39T-$-194.19T-$-321.51T-$-290.73T-$-32.78T
Depreciation and amortization$0.00$2.24T$3.42T$3.61T$397.8B
Stock-based compensation$0.00$0.00$0.00$0.00-$-172.79B
Change in working capital$40.8T-$-1.84T-$-10.65T-$-20.94T-$-37.59B
Accounts receivable-$-3.08T-$-35.6T-$-4.28T-$-1.6T-$-37.59B
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-375.74T-$-164.95T-$-249.58T-$-299.92T-$-263.82T
Investments in property, plant and equipment$0.00$0.00$0.00-$-3T$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-600.51T$149T-$-144.46T$74T-$-6.96T
Common stock issued$455.1T$882.1T$500.4T$200T$316.8T
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$430.5T$834.1T$470.9T$187T$316.6T
Net change in cash-$-577.85T$822.4T$76.8T-$-37.4T$2.3T
Cash at end of period$578.1T$1,156T$333.6T$256.8T$32.5T
Operating cash flow-$-375.74T-$-164.95T-$-249.58T-$-299.92T-$-263.82T
Capital expenditure$0.00$0.00$0.00-$-3T$0.00
Free cash flow-$-375.74T-$-164.95T-$-249.58T-$-302.92T-$-263.82T
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Vicore Pharma Holding AB

        Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The company was founded in 2000 sand is headquartered in Stockholm, Sweden.

        CEO
        Ahmed Mousa
        Employees
        37
        Beta
        0.15

        Explore

        Frequently asked questions

        What is the intrinsic value of Vicore Pharma Holding AB (VCRE)?

        InvestorsCraft does not currently publish an intrinsic value for VCRE. How the IC value is calculated.

        Is VCRE undervalued?

        InvestorsCraft does not publish an undervaluation signal for VCRE at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.